» Articles » PMID: 34993886

Effective Long-term Management of Parathyromatosis-related Refractory Hypercalcemia with a Combination of Denosumab and Cinacalcet Treatment

Overview
Specialty Endocrinology
Date 2022 Jan 7
PMID 34993886
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Parathyromatosis is a rare cause of persistent or recurrent primary hyperparathyroidism and hypercalcemia due to the presence of hyperfunctioning foci of parathyroid tissue in the neck and/or mediastinum. We describe the case of a male patient who presented with severe hypercalcemia and a left-sided palpable parathyroid mass. Over the course of the next 18 years, the patient underwent neck exploration surgery on multiple occasions due to recurrent primary hyperparathyroidism and refractory hypercalcemia, complicated by nephrolithiasis and impairment of renal function, while bone mineral density was preserved. Histological findings and the natural course of the disease were consistent with parathyromatosis. Medical interventions with oral bisphosphonates or high-dose cinacalcet failed to control the patient's hypercalcemia. The combination of monthly denosumab and cinacalcet was, however, successful in maintaining the patient's serum calcium in the normal/upper-normal range over a 36-month period with no significant side effects. This is the first report of off-label denosumab use in combination with cinacalcet in the long-term management of parathyromatosis-related refractory hypercalcemia.

Citing Articles

Recurrent parathyromatosis in a patient with concomitant MEN1 and CASR gene alterations: Clinical management of a case report and literature review.

Sapuppo G, Giusti M, Arico D, Masucci R, Tavarelli M, Russo M Front Endocrinol (Lausanne). 2023; 14:1108278.

PMID: 36998475 PMC: 10044612. DOI: 10.3389/fendo.2023.1108278.


Molecular and Clinical Spectrum of Primary Hyperparathyroidism.

Jha S, Simonds W Endocr Rev. 2023; 44(5):779-818.

PMID: 36961765 PMC: 10502601. DOI: 10.1210/endrev/bnad009.


Two-way Road of Kidney and Hypercalcemia: A Narrative Review.

Aghsaeifard Z, Alizadeh R Cardiovasc Hematol Disord Drug Targets. 2022; 22(4):200-206.

PMID: 36475333 DOI: 10.2174/1871529X23666221205143041.


Parathyroid Carcinoma All-In-One, a Rare Life-Threatening Case With Multiple Systemic Manifestations: Case Report and Review of the Literature.

Zelano L, Locantore P, Rota C, Policola C, Corsello A, Rossi E Front Endocrinol (Lausanne). 2022; 13:881225.

PMID: 35872978 PMC: 9300921. DOI: 10.3389/fendo.2022.881225.

References
1.
Reddick R, Costa J, Marx S . Parathyroid hyperplasia and parathyromatosis. Lancet. 1977; 1(8010):549. DOI: 10.1016/s0140-6736(77)91414-3. View

2.
Hage M, Salti I, Fuleihan G . Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism. Metabolism. 2012; 61(6):762-75. DOI: 10.1016/j.metabol.2011.11.001. View

3.
Scorza A, Moore A, Terry M, Bricker L . Secondary parathyromatosis in a patient with normal kidney function: review of diagnostic modalities and approaches to management. Endocr Pract. 2013; 20(1):e4-7. DOI: 10.4158/EP13053.CR. View

4.
Fernandez-Ranvier G, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E . Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?. Cancer. 2007; 110(2):255-64. DOI: 10.1002/cncr.22790. View

5.
Fountas A, Andrikoula M, Giotaki Z, Limniati C, Tsakiridou E, Tigas S . The emerging role of denosumab in the long-term management of parathyroid carcinoma-related refractory hypercalcemia. Endocr Pract. 2015; 21(5):468-73. DOI: 10.4158/EP14410.OR. View